Á lódáil...
A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were a...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Russo |
| Foilsithe: |
Remedium Group LLC
2019-06-01
|
| Sraith: | Медицинский совет |
| Ábhair: | |
| Rochtain Ar Líne: | https://www.med-sovet.pro/jour/article/view/3060 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|